The Pneumococcal Vaccines Market, estimated at USD 9.38 Bn in 2025, is expected to exhibit a CAGR of 5.1% and reach USD 13.29 Bn by 2032.
The market growth is fueled by rising demand for advanced biotechnology solutions that improve healthcare outcomes, along with increasing adoption in areas such as drug development, diagnostics, and personalized medicine. Innovations in genomics, cell and gene therapies, and biomanufacturing, supported by strong R&D investments, are enhancing treatment effectiveness, efficiency, and accessibility. Furthermore, favorable regulatory support, strategic collaborations, and the growing focus on precision medicine are accelerating market expansion and opening new opportunities for industry participants.
Market Dynamics:
Increasing government initiatives to expand immunization programs along with rising awareness regarding pneumococcal disease prevention can boost demand for pneumococcal vaccines during the forecast period. Various governments across the globe are investing heavily to strengthen their immunization programs, in order to reduce the burden of pneumonia through effective vaccination. For instance, Gavi, the vaccine alliance, announced USD 3.5 billion pneumococcal AMC investment to subsidize vaccines for usage in low-income countries. Continuous growth in adult population susceptible to pneumococcal pneumonia coupled with ongoing changes in serotype epidemiology can boost need for updated vaccines with broader coverage.
Increasing incidences of pneumococcal diseases can drive the market growth
Global pneumococcal vaccines market growth is driven by rising incidence of pneumococcal diseases globally. Pneumonia is one of the leading causes of death among children under 5 years of age. According to the WHO, pneumonia caused over 800,000 deaths in children under 5 years in 2017. The introduction of pneumococcal conjugate vaccines (PCVs) has proved effective in reducing the burden of pneumococcal pneumonia. Increasing awareness about pneumococcal vaccines and government programs for immunization of children can drive the market growth.
Growing elderly population can boost demand for pneumococcal vaccines
Rising elderly population worldwide who are at a higher risk of pneumococcal diseases can also drive the market growth. People aged 65 years or older are more prone to invasive pneumococcal disease as compared to younger people. As life expectancy increases across the globe, the number of elderly people is projected to double from 12% to 22% between 2015 and 2050. With aging population more susceptible to pneumococcal infections, there will be huge demand for pneumococcal vaccines for adults in the near future.
High cost of vaccines can hamper the market growth Global pneumococcal vaccines market growth can be hampered due to their high cost, which restricts their widespread adoption, especially in low and middle-income countries. For instance, Prevnar 13, the leading PCV costs around US$ 150- US$ 200 per dose. The high cost of R&D and clinical trials required to develop new generation vaccines increases cost of vaccine. This poses affordability issues for public healthcare systems and individuals in underdeveloped regions.
Unavailability of vaccines in low resource settings hampers the market growth
Lack of availability and accessibility of pneumococcal vaccines in developing Asian, African countries where the disease burden is highest, can hamper the market growth. As per the WHO, only 31% of the vulnerable children in the developing world received the three recommended doses of PCVs in 2018. The reason is the non-inclusion of the vaccines in the national immunization programs of many poorer nations due to their high prices. This shortfall in availability of vaccines in resource-poor settings can hamper the market growth.
Development of low-cost vaccines can offer market opportunities
Development of affordable low-cost pneumococcal vaccines can offer growth opportunities for market players. As pricing is a major limitation for mass immunization in middle and low-income countries, there is scope for manufacturers to develop low-priced vaccines to tap the largely untapped growth potential in these regions.
Expanding adult immunization programs can open new revenues
Increasing focus on adult pneumococcal immunization globally can offer market growth opportunities. Several markets like the U.S., U.K., Germany have now included pneumococcal vaccines for at-risk populations aged over 65 years in their national programs. As more countries prioritize adult pneumococcal immunization, it will boost demand and offer lucrative scope for vaccine makers to penetrate adult market segments. As pneumococcal disease remains a major public health issue, the market has potential to grow with advancements in vaccines and pricing solutions.
Link - https://www.coherentmarketinsights.com/market-insight/pneumococcal-vaccines-market-2295
Key Developments:
- In June 2024, Merck’s CAPVAXIVE (21-valent pneumococcal conjugate vaccine) was approved by U.S. FDA for preventing invasive pneumococcal disease and pneumonia in adults 18 and older. It targets serotypes responsible for most IPD cases in older adults and showed strong immune responses in clinical trials.
- In April 2024, Merck announced the results of the STRIDE-10 phase 3 clinical trial for its investigational 21-valent pneumococcal conjugate vaccine designed for adults
- In March 2024, Vaxcyte completed enrollment for its phase-2 clinical trial assessing the 24-valent pneumococcal conjugate vaccine candidate VAX-24, aimed at combating invasive pneumococcal disease (IPD) in children
- In January 2024, Pfizer Inc. received marketing authorization from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for its 20-valent pneumococcal conjugate vaccine candidate (20vPnC)
- In October 2023, Vaxcyte, Inc. entered into a new commercial manufacturing agreement with Lonza, aiming to expand its production capacity for its pneumococcal conjugate vaccine candidates
Key Players:
Pfizer Inc., Merck & Co., Inc., GlaxoSmithKline plc (GSK), Sanofi, CSL Limited, Serum Institute of India Pvt. Ltd., Vaxcyte, Inc., Astellas Pharma Inc., Panacea Biotec Ltd., Walvax Biotechnology Co., Ltd., Beijing Minhai Biotechnology Co., Ltd., Merck KGaA, Takeda Pharmaceutical Company Limited, AbbVie Inc., Novartis AG, Johnson & Johnson, Biovac, Bharat Biotech, Inovio Pharmaceuticals, Inc., Hilleman Laboratories Pvt. Ltd
Contact Us